TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells

Cancer Letters

Volumn 361, Issue 1, 2015, Pages 49-56

  Boes, Marianne ^a   Meyer Wentrup, Friederike ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Immune checkpoint blockade; Immune therapy; Neuroblastoma; PD 1 PD L1; Therapeutic antibodies; TLR ligands in cancer therapy

Indexed keywords

INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; POLYINOSINIC POLYCYTIDYLIC ACID; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA; CD274 PROTEIN, HUMAN; TLR3 PROTEIN, HUMAN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; UPREGULATION; ADULT; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; NEUROBLASTOMA; PATHOLOGY; TUMOR CELL CULTURE;

ADULT; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; LYMPHOCYTE ACTIVATION; NEUROBLASTOMA; POLY I-C; TOLL-LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 84925047708     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.02.027     Document Type: Article

References (22)

1. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
2. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med 2010, 363:1324-1334.
3. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med 2012, 366:2455-2465.
4. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 2012, 366:2443-2454.
5. Kataoka Y., Matsumura T., Yamamoto S., Sugimoto T., Sawada T. Distinct cytotoxicity against neuroblastoma cells of peripheral blood and tumor-infiltrating lymphocytes from patients with neuroblastoma. Cancer Lett 1993, 73:11-21.
6. Gowda M., Godder K., Kmieciak M., Worschech A., Ascierto M.L., Wang E., et al. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J. Transl. Med 2011, 9:170.
7. Brodeur G.M., Bagatell R. Mechanisms of neuroblastoma regression. Nat. Rev. Clin. Oncol 2014, 11:704-713.
8. Zhou Y., Guo M., Wang X., Li J., Wang Y., Ye L., et al. TLR3 activation efficiency by high or low molecular mass poly I:C. Innate Immun 2013, 19:184-192.
9. Pistoia V., Morandi F., Bianchi G., Pezzolo A., Prigione I., Raffaghello L. Immunosuppressive microenvironment in neuroblastoma. Front. Oncol 2013, 3:167.
10. Bill A.H., Morgan A. Evidence for immune reactions to neuroblastoma and future possibilities for investigation. J. Pediatr. Surg 1970, 5:111-116.
11. Chuang J.H., Chuang H.C., Huang C.C., Wu C.L., Du Y.Y., Kung M.L., et al. Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells. J. Biomed. Sci 2011, 18:65.
12. Hsu W.M., Huang C.C., Wu P.Y., Lee H., Huang M.C., Tai M.H., et al. Toll-like receptor 3 expression inhibits cell invasion and migration and predicts a favorable prognosis in neuroblastoma. Cancer Lett 2013, 336:338-346.
13. Lee S.K., Seo S.H., Kim B.S., Kim C.D., Lee J.H., Kang J.S., et al. IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. J. Dermatol. Sci 2005, 40:95-103.
14. Raffaghello L., Prigione I., Bocca P., Morandi F., Camoriano M., Gambini C., et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005, 24:4634-4644.
15. Hartmann G., Battiany J., Poeck H., Wagner M., Kerkmann M., Lubenow N., et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol 2003, 33:1633-1641.
16. Castriconi R., Dondero A., Bellora F., Moretta L., Castellano A., Locatelli F., et al. Neuroblastoma-derived TGF-beta1 modulates the chemokine receptor repertoire of human resting NK cells. J. Immunol 2013, 190:5321-5328.
17. Yang K.D., Shaio M.F., Wang C.L., Wu N.C., Stone R.M. Neuroblastoma cell-mediated leukocyte chemotaxis: lineage-specific differentiation of interleukin-8 expression. Exp. Cell Res 1994, 211:1-5.
18. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res 2008, 14:6735-6741.
19. Ferrer F.A., Pantschenko A.G., Miller L.J., Anderson K., Grunnet M., McKenna P.H., et al. Angiogenesis and neuroblastomas: interleukin-8 and interleukin-8 receptor expression in human neuroblastoma. J. Urol 2000, 164:1016-1020.
20. Brignole C., Marimpietri D., Di Paolo D., Perri P., Morandi F., Pastorino F., et al. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res 2010, 70:9816-9826.
21. Lahoud M.H., Ahmet F., Zhang J.G., Meuter S., Policheni A.N., Kitsoulis S., et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:16270-16275.
22. Skold A.E., Hasan M., Vargas L., Saidi H., Bosquet N., Le Grand R., et al. Single-stranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood 2012, 120:768-777.